Enveric Biosciences, INC 8-K filings

Enveric Biosciences reported second quarter 2026 financial results and provided a corporate update, highlighting advancements in its EB-003 development program and securing new patents.

Enveric Biosciences has filed a prospectus supplement to sell up to $2.425 million in common stock through an existing At-The-Market (ATM) facility.

Enveric Biosciences shareholders approved key governance proposals, including a reverse stock split and authorized share increase, at the 2026 Annual Meeting.

Enveric Biosciences reported Q1 2026 financial results, highlighting progress in its lead drug candidate EB-003 development and a strengthened IP portfolio, alongside a net loss of $1.6 million.

Enveric Biosciences announced its fourth quarter and full-year 2025 financial results, highlighting positive preclinical data for its lead drug candidate EB-003 and strengthening its intellectual property portfolio.

Enveric Biosciences, Inc. filed a prospectus supplement to register an additional $1.346 million in common stock shares for its At-The-Market offering.

Enveric Biosciences completed a registered direct offering and concurrent private placement, raising approximately $1.5 million in gross proceeds to fund product development and working capital.

Enveric Biosciences, Inc. announced the release of its Q1 2026 Investor Presentation, available on its website and furnished as an exhibit to its latest 8-K filing.

Enveric Biosciences raised approximately $3.1 million in gross proceeds by inducing existing warrant holders to exercise their warrants at a reduced price, issuing new Series E and F warrants.

Enveric Biosciences' stockholders approved proposals for a reverse stock split, an increase in authorized shares, and warrant issuance compliance at a Special Meeting.

Enveric Biosciences, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing the matter.

Enveric Biosciences reported its third quarter 2025 financial results and provided a corporate update, highlighting progress on its lead candidate EB-003 towards clinical trials and intellectual property defense.

Enveric Biosciences announced a 1-for-12 reverse stock split and addressed Nasdaq delisting notices regarding minimum bid price and stockholders' equity.

Enveric Biosciences secured approximately $2.2 million in gross proceeds by inducing holders to exercise existing warrants at a reduced price, issuing new warrants in return.

Enveric Biosciences announced the relocation of its corporate headquarters to Cambridge, Massachusetts, to leverage the region's scientific and financial ecosystem and advance its lead candidate, EB-003.

Enveric Biosciences, Inc. has furnished its Q3 2025 Investor Presentation, which will be available on its website and used for future investor engagements.

Enveric Biosciences received a Nasdaq deficiency letter for failing to meet the minimum stockholders' equity requirement, risking its continued listing.

Enveric Biosciences announced its second quarter 2025 financial results and provided a comprehensive business update, highlighting significant progress in its lead drug candidate EB-003 and intellectual property expansion.

Enveric Biosciences, Inc. stockholders approved a conditional reverse stock split, ranging from 1:5 to 1:50, to be enacted if the company faces a Nasdaq delisting due to minimum bid price non-compliance before January 28, 2026.

Enveric Biosciences announced its first quarter 2025 financial results, highlighting progress in its neuroplastogenic therapeutic development and expansion of its intellectual property portfolio.

Enveric Biosciences dismisses Marcum LLP as its independent auditor and engages CBIZ CPAs, effective April 14, 2025.

Enveric Biosciences reports financial results for Q4 and fiscal year 2024, highlighting advancements in its neuroplastogen program and strategic out-licensing deals.

Enveric Biosciences, Inc. announced that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the bid price rule, as of March 4, 2025.

Enveric Biosciences, Inc. releases an investor presentation on its website, providing updates to current and potential stakeholders.

Enveric Biosciences has successfully closed a public offering, raising approximately $5 million to support working capital, EB-003 development, and general corporate purposes.

Enveric Biosciences has amended the start date for trading of its common stock on a reverse stock split-adjusted basis to January 29, 2025.

Enveric Biosciences has executed a 1-for-15 reverse stock split, effective January 27, 2025, to consolidate its shares and maintain Nasdaq listing compliance.

Enveric Biosciences has released an investor presentation on its website, which may be used in future communications with various stakeholders.

Enveric Biosciences received a delisting notice from Nasdaq after failing to maintain a minimum share price of $1.00, and the company intends to appeal the decision.

Enveric Biosciences reported progress on its lead drug candidate EB-003 and announced third quarter 2024 financial results, including out-licensing agreements.